EXCLUSIVE: FibroBiologics Releases First Batch Of CYWC628 Drug Product For Phase 1/2 Diabetic Foot Ulcer Trial, Positions To Start Patient Enrollment

Benzinga Newsdesk www.benzinga.com Positive 49.9%